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Purpose: Here we report the results of a review of a prospectively maintained database of
the use polyacrylate polyalcohol copolymer (PPC) injection to correct grades IV and V VUR.
Materials and Methods: All children with grades IV andV primaryVUR that presented with
febrile urinary tract infection while on prophylaxis, in a 3-year period, were treated with a
sub-ureteral injection of PPC. Institutional ethical approval was obtained. Exclusion criteria
were incomplete bladder emptying documented on videourodynamic study, ureteral dupli-
cation, paraureteral diverticula, and poor ureteral emptying observed during fluoroscopy
and previous open surgical or endoscopic treatment. Pre- and post-operative evaluation
included urinalysis, renal and bladder ultrasonography, DMSA scan, and videourodynamic
studies.
Results: Thirty-three children [36 renal units (RU)] were included with a median age of
57 months (range 7–108). There were 18 boys and 15 girls. Thirty RU had grade IV and 6
grade V VUR. Median follow-up time was 32 months (range 7–58). Reflux was cured in
32/36 RU with the first injection, but another two patients were reimplanted because of
dilatation. Complications included early urinary tract infection in seven children, transient
lower urinary tract symptoms in five children. Progressive ureteral dilatation was noted
in four children and was treated with insertion of a double J stent. Two of these children
eventually required an ureteroneocystostomy.
Conclusion: The use of PPC to treat grades IV and V vesicoureteral reflux in young chil-
dren has an overall success rate of 83.3%. Persistent ureteral dilatation was present in
11% associated with high injection volume. Future studies will attempt to maintain a high
success rate reducing the volume of injection and the incidence of dilatation.
Keywords: endoscopic injection, high grade vesico-ureteral reflux, vantris, polyacrylate polyalcohol copolymer,
children
INTRODUCTION
The treatment of grades IV and V primary vesicoureteral reflux
(HGVUR) is dependent on the age of the child, symptoms,
and status of the kidneys. Given the high-resolution rate of
reflux in children, medical treatment with antibiotic prophy-
laxis is preferred (1). However, the resolution rate of HGVUR
is low (1). When surgical treatment is required because of non-
resolution, breakthrough infections, or low expectation of sponta-
neous resolution, many urologists choose the endoscopic injec-
tion. There is a parental preference for endoscopic treatment.
This carries an acceptable success rate with lower morbidity
and cost, no scars, as an outpatient procedure (2, 3). The ini-
tial experience with polyacrylate polyalcohol copolymer (PPC)
in a multicenter study in all grades of VUR had an 83.6% suc-
cess rate (3). The possible benefit of PPC for treating HGVUR
is the long term of the results since it is a non-absorbable
substance.
Here we report the results with the use of a new substance, PPC
(Vantris®-Promedon Argentina) in a single center study including
only patients with primary HGVUR.
MATERIALS AND METHODS
All consecutive children presenting with febrile urinary tract infec-
tions (UTI) under prophylaxis and HGVUR in a 3-year period
at one institution were included in this study. The patients were
enrolled prospectively. Institutional ethical approval was obtained.
All patients had received antibacterial prophylaxis from 6 to
18 months, in 5 there was a prenatal history of urinary tract
dilatation. Exclusion criteria were bladder and bowel dysfunction,
ureteral duplication, paraureteral diverticula, poor ureteral emp-
tying observed during fluoroscopy, and previous open surgical
or endoscopic treatment. We considered good ureteral emptying
when there was no residual contrast in the ureter at the end of
voiding.
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Preoperative evaluation consisted of urinalysis and culture,
renal and bladder ultrasonography, DMSA scan, and videouro-
dynamic studies. Post-operative studies included renal and blad-
der ultrasonography, urinalysis and culture 10 days, 3, 6, and
12 months after the procedure. DMSA scan and videourodynamic
studies were repeated 1 year post-operatively.
Reflux was graded according to the international grading sys-
tem, based on the voiding cystourethrogram performed at the time
of the videourodynamic studies.
Success was defined as the elimination of HGVUR with a single
injection.
Complications were classified as UTI, progressive ureteral
dilatation, new renal damage, or persistent reflux. Decreases in
the differential renal function of more than 5% or the appear-
ance of new scars were considered evidence of new renal damage.
Obstruction was defined as progressive ureteral dilatation of more
than 5 mm, 3 months after the procedure.
Clinical data were collected in a prospective manner. Patient
demographics, the presence lower urinary tract symptoms (LUTS),
ureteral and upper tract dilatation, UTI, presence or absence
of VUR at 12 months, and changes in DMSA scan were
recorded.
All patients were injected with PPC. This is non-absorbable
substance, with average particle size of 320µm, causes minimal
inflammatory reaction and it and does not migrate.
SURGICAL TECHNIQUE
The endoscopic injection was performed under general anesthesia
following established techniques. A 10 Ch cystoscope was used.
The injection was performed manually with a 1 ml syringe pro-
vided by the manufacturer, through a 23G needle. We used the
hydrodistention technique (4) and injected intra- and sub-ureteral
until the ureteral walls coapted.
Patients were kept on antibacterial prophylaxis for 10 days
after the procedure unless the first ultrasound showed ureteral
dilatation.
RESULTS
Thirty-three patients were included [36 renal units (RU)]. Another
27 patients with HGVUR were operated in the same period but
match the exclusion criteria. The median age was 57 months (range
7–108), 18 were males and 15 females. Thirty-six RU were treated.
Of these 20 were on the right side, 10 on the left, and 3 bilateral.
HGVUR was grade IV in 30 and grade V in 6 RU. Twenty-one
of the RU had abnormalities on the DMSA scan preoperatively.
The mean volume injected was 2 ml (range 1–3 ml). The median
follow up period was 32 months (range 7–58 months).
ELIMINATION OF REFLUX
Videourodynamic study at 1 year after the procedure revealed
HGVUR resolution in 32 of 36 RU (88.9%) of the RU with per-
sistent reflux, 4 had grade IV in the preoperative evaluation. The
mean injected volume of PPC 2 ml (1–3 ml).
COMPLICATIONS
Post-operative febrile UTI were observed in nine patients, 7 (21%)
during first 2 weeks after surgery but they did not recur despite
absence of antibacterial prophylaxis and 2 (6%) recurrent UTI
associated to persistent VUR. Five children (15%) had transient
LUTS as urgency-frequency managed with anticholinergics.
Ten patients (27%) had ureteral dilatation on the first ultra-
sound, but only in four the ureter stay dilated and in fact the
progressive dilatation increased extending to the proximal urinary
tract at the 3-month control. A double J stent was inserted in these
four patients for a 4-month period. Two of these patients had a
dilated ureter preoperatively. In two cases the dilatation resolved
after removal of the stent. The other two patients underwent a uni-
lateral extravesical ureteroneocystostomy for persistent dilatation
after removal of the JJ stent. All dilated ureters had been injected
with 2.5–3 ml of PPC.
DMSA scans were obtained at 1 year in 19 patients. In three
cases changes were observed compared to the preoperative scan.
One girl with persistent reflux and a febrile UTI developed a new
scar. Another girl with persistent grade III reflux suffered a 7%
reduction in differential function. Finally one asymptomatic boy
with reflux resolution and without dilatation also suffered an 8%
decrease in function on the involved side and was considered as a
technical error.
The four patients (4 RU) with persistent reflux also under-
went unilateral extravesical ureteroneocystostomy. The overall
success rate was 83.3% including the persistent reflux and the
two patients who require a reimplantation because of persistent
ureteral dilatation.
DISCUSSION
The management of vesicoureteral reflux has been a matter of
debate for decades. The potential advantages of surgical versus
medical treatment with prolonged administration of antibacter-
ial prophylaxis had not been defined yet (1). More recently, the
role of antibiotic prophylaxis has been also questioned (5). These
uncertainties have not prevented progress in the development of
endoscopic injection of bulking substances to treat reflux (2).
Following the initial report by Matouschek in 1981 (6),
O’Donnell and Puri (7) demonstrated the successful the use of
ethylene polytetrafluoro paste (Teflon) injected sub-ureterally to
control reflux. However, concerns regarding potential migration of
the substance, the formation of granulomas, and lack of approval
by the US Food and Drug Administration (FDA), hampered the
wide spread application of this treatment outside Ireland and a
few other countries (8).
Polydimethylsiloxane paste was shown not to migrate and was
also effective to control reflux. Although it remains the subject
of occasional reports, injection of this substance, which is very
viscous, requires a special pressure syringe a method many find
cumbersome. Again, failure to obtain FDA approval limited its use
in the US (9).
The use of cross-linked bovine dermal collagen failed to obtain
wide spread acceptance because of low success rate and durability
and the need to perform sensitivity tests prior to the injection.
The landscape of endoscopic injection for the treatment of reflux
rapidly changed with the appearance of hyaluronan/dextranomer
copolymer (Deflux®) after the acceptance by the FDA and in many
centers became a first line of treatment for vesicoureteral reflux
(10). Whereas some authors have reported excellent success for
HGVUR with up to three injections (11), others have shown only
41% cure rate for grade IV reflux (12).
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In 2008, we reported the development of a new agent design
for endoscopic treatment of vesicoureteral reflux, namely PPC.
The product is quite fluid and can be injected with and ordinary
syringe through a 23 G needle (13).
The preliminary results from a multicenter study demonstrated
an 83.6% elimination of reflux with a single injection. However in
that series the majority of the patients had grades II and III reflux
(3). In the present study we report the results of injection of PPC
in grades IV and V reflux.
This study is unique in that all patients underwent a post-
operative study 1 year after the injection to determine the presence
of VUR. We chose to do videourodynamic studies pre and post-
operatively since we have this capability readily available in our
imaging department.
At the onset we decided to exclude patients with slow drainage
of the upper tracts following reduction of voiding pressures emp-
tying (poor ureteral emptying), since they may have an element of
ureterovesical obstruction that may affect outcome.
We succeeded in curing HGVUR in 89% (32/36) of the ureters
treated with a single injection, but two other patients needed to
be reimplanted because of persistent ureteral dilatation with a
final success rate of a 83%. This success rate is comparable as that
reported in other series (11). Also, we did not consider patients
with residual low grade reflux as cured. This is a small num-
ber of patients and further studies are needed to reach statistical
significance.
The early US show a 27% transient ureteral dilation, mostly
because of post-operative edema and UVJ obstruction.
Our rate of obstruction (at 3 months US) requiring treatment
was 11% (4/36) and 5.6% (2/36) required open surgical treat-
ment for persistent ureteral dilatation. Two of the four patients
dilated had dilated ureter prior to the injection. Since the four
patients had symptoms and progressive dilatation on ultrasound,
we did not considered a renal scintigraphy necessary to confirm
the obstruction.
Vandersteen et al. reported a 0.7% obstruction with dextra-
nomer/hyaluronic acid copolymerin in 1,155 ureters treated injec-
tion, managed only with a stent (14). Mazzone et al reported the
highest complication rate with the same substance in 5.7% of 87
ureters (15).
The reason a substance may fail could be because of the tech-
nique used (volume used and/or place of injection), inflamma-
tory reaction or the substance itself. In these four patients with
persistent ureteral dilatation the volume injected exceeded 2 ml.
The incidence of post-operative febrile UTI during first 2 weeks
after surgery in this series (21%) (7/33) was comparable to that
reported by Sedberry-Ross et al (16). In their series, early febrile
UTIs were predictive of treatment failure even in the absence of
reflux in an early voiding cystourethrogram. Longer follow up is
needed to determine if this will also be the case with PPC. The 15%
(5/33) incidence of LUTS in this series was transient and unrelated
to either infection or obstructive complications.
The weakness of this study is the small number of patients
and the strengths is the long-term follow up of a non-absorbable
substance.
In summary, our experience with the use of PPC to treat pri-
mary HGVUR has been favorable. Since some reports suggest that
results with the use of Deflux® may not be durable (17), the use
of a non-biodegradable substance with minimum inflammatory
reaction such as PPC may obviate this shortcoming and risk of
obstruction of endoscopic treatment. To test this hypothesis we
plan long-term follow up of our patients. Future protocols will
attempt to reduce the volume of substance injected and expect to
maintain the high success rate with a single injection.
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